EVAX (Evaxion Biotech AS) יחס יתרת חוב לטווח ארוך להון

The development of Evaxion Biotech A/S (EVAX) relies on patenting its own AI models without the use of M&A. However, the lack of revenue and high forecast uncertainty create significant risks. Diversification of cancer-fighting programs provides stability. The history of long-term debt load on capital demonstrates a level of support where the parameter value reaches 0.71, confirming the issuer's current financial stability.

Evaxion Biotech A/S (EVAX) develops AI platforms for the creation of personalized anti-tumor vaccines and B2B partnerships. This metric determines the company's reliance on long-term borrowings relative to its own equity. The current long-term debt-to-equity ratio is calculated by dividing loans with a maturity of more than one year by the shareholder value. This allows for an assessment of financial stability during the large-scale expansion of software. It is critical for investors to understand how effectively the business finances innovation without excessive credit risk.